

Balerna (Switzerland), 18th May 2015

New clinical data on the role of Nexodyn™ in the management of infected chronic wounds of the lower leg presented at EWMA (European Wound Management Association, London, 13-15 May 2015)

APR Applied Pharma Research s.a. (“APR”), the Swiss, independent developer of science-driven, patent-protected healthcare products, communicates that new clinical data on the role of Nexodyn™, an AcidOxidizing spray solution, in the management of infected chronic wounds have been presented by Elia Ricci, MD, and colleagues at the EWMA (European Wound Management Association) 2015 Conference in London (May 13 – 15).

These data clearly demonstrates that the use of Nexodyn alone is able to control the local bioburden in wounds showing clinical signs of infection and provides local microenvironmental modulation helping wounds reset and restart a physiological healing process, a hot topic in the bio-medical field.

The presented data report the results of a retrospective analysis on 9 patients with infected chronic ulcers of different etiology which were showing unsatisfactory progress with standard therapies. With the objective of providing patients with a cleansing treatment able to satisfactorily control the local signs of infection, patients included in analysis received Nexodyn™ once daily for 4 weeks with no other active treatment.

After 4 weeks of treatment with Nexodyn only, used to cleanse the wound bed at each medication, infection rates showed a statistically significant reduction of local infection, with 75% of patients devoid of any signs of local infection. In parallel, indicators of the wound bed quality and its microenvironment, such as the WBP Total Score, the multi-factorial Bates-Jensen Score showed significantly improved wound conditions. The progressive evaluation of an easy-to-measure indicator of the local microenvironmental conditions, the local pH, whose decrease is an indicator of wound healing, showed a trend of reduction despite the relatively short observation time. In addition, wound-associated pain decreased significantly, providing a definitive benefit to patients.

In the context of EWMA 2015, APR is proud to announce to be one of the sponsors of the Antimicrobial Stewardship in Wound gathering worldwide renown experts discussing on the topic: "Combatting Antimicrobial Misuse in Wound Care".

A recognized general misuse of systemic and local antibiotics, together with the alarming raise of multi-resistant bacterial strains, pose important challenges to wound management, where one of the most frequent complications is certainly infection.

The Antimicrobial Stewardship in Wound Management has the objective to strengthen the knowledge of all the healthcare stakeholders by setting the basis for the identification of best practices in prevention, diagnosis and treatment of wound infection and to foster education in the chronic wound setting.

About Nexodyn™

Nexodyn is an AcidOxidizing spray solution, characterized by pH<3, RedOx >1000mV and stabilized hypochlorous acid (>95% of free chlorine species) - intended for use in the debridement, irrigation and moistening of acute and chronic wounds, ulcers, cuts, abrasions, burns and other lesions.

Nexodyn has been developed based on APR's proprietary and patented technology TEHCLO®, enabling the production of super-oxidized solutions containing free chlorine species, of which stabilized hypochlorous acid (HClO) in very high concentration (> 95%). A wide array of non-clinical experiments and clinical observations suggest Nexodyn to act as a valid support to the activation of the physiological processes that restart wound healing, in presence of a favorable safety and tolerability profile.

The convenient and easy-to-use spray formulation completes Nexodyn's profile, providing healthcare professionals with a new tool for an optimized wound care.

About APR Applied Pharma Research s.a.

APR is a Swiss, independent developer of science driven, patent protected Healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in selected therapeutical areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally

developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.

For press releases and other company information visit: www.apr.ch

Contacts:

APR Applied Pharma Research s.a.

Paolo Galfetti; CEO

T: +41 91 6957020 or email to paolo.galfetti@apr.ch